Candida auris fungal infections tripled in the United States between 2019 and 2021 to 1,471, including seven cases resistant to all antifungal treatments, according to Centers for Disease Control and Prevention data reported yesterday in the Annals of Internal Medicine. Twenty-eight states and Washington, D.C., have reported cases since the first U.S. infection in 2013. While not a threat to healthy people, C auris infections “tend to occur in patients who have multiple or prolonged health care encounters or indwelling devices, including those receiving mechanical ventilation,” the authors note.
 
“The rapid rise and geographic spread of cases is concerning and emphasizes the need for continued surveillance, expanded lab capacity, quicker diagnostic tests, and adherence to proven infection prevention and control,” said Meghan Lyman, a CDC epidemiologist and lead author of the paper.
 

Related News Articles

Headline
The Administration for Strategic Preparedness and Response June 25 announced a flu pandemic preparedness and response strategy in response to the threat of…
Headline
The Centers for Disease Control and Prevention June 25 issued a Health Alert Network Health Advisory about an increased risk of dengue virus infections in the…
Headline
The Food and Drug Administration last week granted enforcement discretion for the use of conjunctival swabs by laboratories as part of human testing for H5N1…
Headline
The Centers for Disease Control and Prevention May 21 announced recommendations that flu surveillance systems continue operating at enhanced levels during the…
Headline
Pediatric sepsis is "an aggressive and unrelenting adversary that knows neither geographic nor demographic bounds," writes Chris DeRienzo, M.D., AHA’s senior…
Headline
Centers for Disease Control and Prevention and state and territorial public health officials Friday met to discuss preparedness planning for bird flu after one…